The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active Ulcerative Colitis: Phase 2b QUASAR Study results through week 12

被引：0

作者：

Dignass, A. ^{[1
]}

Rubin, D. ^{[2
]}

Bressler, B. ^{[3
]}

Huang, K. H. ^{[4
]}

Shipitofsky, N. ^{[4
]}

Germinaro, M. ^{[4
]}

Zhang, H. ^{[4
]}

Johanns, J. ^{[4
]}

Feagan, B. ^{[5
]}

Sandborn, W. ^{[6
]}

Sands, B. ^{[7
]}

Hisamatsu, T. ^{[8
]}

Lichtenstein, G. ^{[9
]}

Panes, J. ^{[10
]}

Allegretti, J. ^{[11
]}

机构：

[1] Agaples Markus Hosp, Dept Med, Frankfurt, Germany

[2] Univ Chicago Med, Ctr Inflammatory Bowel Dis, Chicago, IL USA

[3] Univ British Columbia, Div Gastroenterol, Vancouver, BC, Canada

[4] Janssen Res & Dev LLC, Immunol, Spring House, PA USA

[5] Western Univ, Robarts Clin Trials, London, ON, Canada

[6] Univ Calif San Diego, Div Gastroenterol, La Jolla, CA USA

[7] Icahn Sch Med Mt Sinai, Dr Henry D Janowitz Div Gastroenterol, New York, NY 10029 USA

[8] Kyorin Univ, Dept Gastroenterol & Hepatol, Tokyo, Japan

[9] Univ Penn, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA

[10] Hosp Clin Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain

[11] Brigham & Womens Hosp, Crohns & Colitis Ctr, Div Gastroenterol Hepatol & Endoscopy, 75 Francis St, Boston, MA 02115 USA

来源：

JOURNAL OF CROHNS & COLITIS | 2022年 / 16卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

OP23

引用

页码：I025 / I026

页数：3

共 50 条

[21] Early Symptomatic Improvement With Guselkumab Induction Treatment in Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Induction Study
Lichtenstein, Gary R.
Dignass, Axel
Rubin, David T.
Yarandi, Shadi
Huang, Kuan-Hsiang G.
Germinaro, Matthew
Miao, Ye
Zhang, Hongyan
Kierkus, Jaroslaw
Seidler, Ursula
Maemoto, Atsuo
Allegretti, Jessica R.
Bressler, Brian
Peyrin-Biroulet, Laurent
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S623 - S624
[22] The Efficacy of Maintenance Treatment with Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 QUASAR Maintenance Study Results at Week 44 by Biologic/Janus Kinase History
Allegretti, Jessica R.
Panes, Julian
Peyrin-Biroulet, Laurent
Sands, Bruce E.
Yarandi, Shadi
Huang, Kuan-Hsiang G.
Germinaro, Matthew
Zhan, Jia
Zhang, Hongyan
Begun, Jakob
Kierkus, Jaroslaw
Kravchenko, Tetiana
Hisamatsu, Tadakazu
Rubin, David T.
Bressler, Brian
Dignass, Axel
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S882 - S882
[23] Guselkumab efficacy and safety in East Asian participants with moderate to severely active Ulcerative Colitis: Subgroup analysis of the Phase 2b/3 QUASAR induction and maintenance studies
Chen, B.
Ye, B. D.
Cao, Q.
Hirai, F.
Saruta, M.
Chen, M.
Pelak, S.
Shipitofsky, N.
Wahking, B.
Zhuo, J.
Hisamatsu, T.
JOURNAL OF CROHNS & COLITIS, 2025, 19 : I2085 - I2086
[24] Efficacy and Safety of Upadacitinib as an Induction Therapy for Patients With Moderately-to-Severely Active Ulcerative Colitis: Combined Results From 382 Subjects in the Phase 2b Study U-ACHIEVE
Higgins, Peter
Hebuterne, Xavier
Siffledeen, Jesse
Zhou, Wen
Cataldi, Fabio
Xie, Wangang
Lacerda, Ana
Danese, Silvio
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S131 - S131
[25] Guselkumab improves abdominal pain and bowel urgency symptoms in patients with moderately to severely active ulcerative colitis: Results from the phase 3 QUASAR induction study
Rubin, D.
Panes, J.
Feagan, B.
Yarandi, S.
Huang, K. H.
Germinaro, M.
Han, C.
Miao, Y.
Zhang, H.
Qiu, Y.
Klopocka, M.
Duvall, G.
Lichtenstein, G.
Hisamatsu, T.
Bressler, B.
Peyrin-Biroulet, L.
JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1816 - I1817
[26] Guselkumab Improves Health-Related Quality of Life in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the QUASAR Phase 3 Induction Study
Bressler, Brian
Feagan, Brian G.
Panes, Julian
Lichtenstein, Gary R.
Huang, Kuan-Hsiang G.
Germinaro, Matthew
Pandya, Dwiti
Han, Chenglong
Miao, Ye
Zhang, Hongyan
Lateef, Syed
Petroniene, Rima
Rayyan, Yaser
Peyrin-Biroulet, Laurent
Rubin, David T.
Hisamatsu, Tadakazu
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S807 - S808
[27] Guselkumab Improves Abdominal Pain and Bowel Urgency Symptoms in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Induction Study
Rubin, David T.
Panes, Julian
Feagan, Brian G.
Yarandi, Shadi
Huang, Kuan-Hsiang G.
Germinaro, Matthew
Han, Chenglong
Miao, Ye
Zhang, Hongyan
Qiu, Yun
Klopocka, Maria
Duvall, George
Lichtenstein, Gary R.
Hisamatsu, Tadakazu
Bressler, Brian
Peyrin-Biroulet, Laurent
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S677 - S677
[28] Efficacy and safety of subcutaneous guselkumab induction therapy in patients with moderately to severely active Crohn's disease: Results through Week 48 from the phase 3 GRAVITI study
Hart, A.
Panaccione, R.
Steinwurz, F.
Danese, S.
Hisamatsu, T.
Cao, Q.
Olurinde, M.
Vetter, M. L.
Yang, Z.
Wang, Y.
Johanns, J.
Terry, N. A.
Sands, B. E.
D'Haens, G.
JOURNAL OF CROHNS & COLITIS, 2025, 19 : i66 - i67
[29] Efficacy and Safety of Subcutaneous Guselkumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease: Results Through Week 48 From the Phase 3 GRAVITI Study
Panaccione, Remo
Hart, Ailsa
Steinwurz, Flavio
Danese, Silvio
Hisamatsu, Tadakazu
Cao, Qian
Olurinde, Mobolaji
Vetter, Marion
Yang, Zijiang
Wang, Yuhua
Johanns, Jewel
Terry, Natalie A.
Sands, Bruce E.
D'Haens, Geert R.
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S740 - S741
[30] Risankizumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomized Phase 3 INSPIRE Study
Louis, Edouard
Panaccione, Remo
Parkes, Gareth
Peyrin-Biroulet, Laurent
Ferrante, Marc
Takeuchi, Ken
Siegmund, Britta
Levine, Phillip
Kalabic, Jasmina
Neimark, Ezequiel
Wallace, Kori
Chen, Su
Duan, W. Rachel
Armuzzi, Alessandro
Biedermann, Luc
Loftus, Edward V.
Melmed, Gil
Schreiber, Stefan
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S624 - S625

← 1 2 3 4 5 →